Antisense oligodeoxynucleotide inhibits D2 dopamine receptor-mediated behavior and D2 messenger RNA.
There are several subtypes of dopamine receptors in the central nervous system which mediate the actions of dopamine in producing its diverse motor and behavioral effects. In this study we determined whether an antisense oligodeoxynucleotide directed to the mRNA encoding one of the subtypes of the dopamine receptor can inhibit a specific dopamine-mediated behavior. Accordingly, the effects of a phosphorothioate-modified antisense oligodeoxynucleotide targeted toward the D2 dopamine receptor mRNA (D2 antisense) was studied in mice with unilateral 6-hydroxydopamine-induced lesions of the corpus striatum. Rotational behavior in response to different agents, and the levels of D2 and D1 dopamine receptors and D2 and D1 dopamine receptor mRNAs in corpus striatum were then measured. In control mice, lesioning resulted in a contralateral rotational behavior in response to the D1 dopamine receptor agonist SKF 38393, the D2 dopamine agonist quinpirole, and the muscarinic cholinergic agonist oxotremorine. Lesioning also caused an increase in D2 dopamine receptor mRNA levels in the dorsolateral striatum. Intraventricular injections of the D2 antisense inhibited rotational behavior induced by quinpirole but not that induced by SKF 38393 or that induced by oxotremorine. Repeated administration of the D2 antisense significantly reduced the levels of the D2 dopamine receptor and D2 dopamine receptor mRNA in the dorsolateral but not the dorsomedial striatum. Similar treatment failed to significantly alter the levels of the D1 dopamine receptor or D1 receptor mRNA in dorsolateral or dorsomedial striatum.(ABSTRACT TRUNCATED AT 250 WORDS)
Weiss
B
B
Department of Pharmacology, Medical College of Pennsylvania, Philadelphia 19129.
Zhou
L W
LW
Zhang
S P
SP
Qin
Z H
ZH
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000494:pharmacology; D000818:Animals; D001483:Base Sequence; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D016373:DNA, Antisense / Q000494:pharmacology*; D018492:Dopamine Antagonists; D004873:Ergolines / Q000037:antagonists & inhibitors / Q000494:pharmacology; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D008969:Molecular Sequence Data; D009043:Motor Activity / Q000187:drug effects* / Q000235:genetics; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology*; D016627:Oxidopamine / Q000633:toxicity; D010095:Oxotremorine / Q000494:pharmacology; D019257:Quinpirole; D012333:RNA, Messenger / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics*; D011954:Receptors, Dopamine / Q000235:genetics; D012399:Rotation
D016373:DNA, Antisense; D018492:Dopamine Antagonists; D004873:Ergolines; D009838:Oligodeoxyribonucleotides; D012333:RNA, Messenger; D011954:Receptors, Dopamine; D019257:Quinpirole; D010095:Oxotremorine; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D016627:Oxidopamine